New Apple Tree biotech emerges with antibodies that might pair with Amgen, Mirati’s KRAS drugs

Apple Tree Partners is out Monday with a new biotech from the labs of NYU Langone Health that aims to tackle drug resistance in cancer.

Aethon Therapeutics will get $25 million from the VC firm, and another $5 million from New York University, the New York-based biotech said Monday.


Click to view original post